Aligos Therapeutics, Inc. (ALGS) Tops Q4 EPS by 6c

Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported Q4 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.68 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Aligos Therapeutics, Inc. (ALGS) click here.

You May Also Be Interested In

• Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• SuperCom (SPCB) Tops Q3 EPS by 43c